Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Vaxart

The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway)

Investors can use a free MarketBeat screener to find popular penny stocks; here are three stocks that may offer speculative upside for risk-tolerant investors

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

From nasal vaccines to pills: the next defences against Covid

From nasal vaccines to pills: the next defences against Covid

Analysis: a bivalent vaccine has been approved and research is being carried out into possible pan-coronavirus vaccines

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Nasal sprays and pills could be 'game-changer' in future fight against Covid-19

There's been an explosion in vaccine research - as an oral Covid-19 inoculation is tested in the US, Jane Symons asks if no-jab vaccines could be the future of immunisation

Recap: Vaxart Q4 Earnings

Vaxart (NASDAQ:VXRT) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Vaxart beat estimated earnings by 11.76%, reporting an EPS of $-0.15 versus an estimate of $-0.17.

This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart

Macy's Inc (NYSE: M) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors.

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Organisations

European Commission

European Medicines Agency

Rhythm Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Pulmonary Fibrosis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

393,467 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play